Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive
September 30 2019 - 11:20AM
Dow Jones News
By Carlo Martuscelli
Roche Holding AG (ROG.EB) said Monday that a study of its cancer
drug Tecentriq had met its objectives, with the drug showing
efficacy in patients with previously untreated, advanced bladder
cancer.
The German company said that data from the Imvigor130 phase 3
clinical trial showed Tecentriq combined with chemotherapy improved
the amount of time before disease progression when compared with
chemotherapy alone. Patients in the study had a form of bladder
cancer called urothelial carcinoma.
Tecentriq is an immunotherapy--a type of medicine that is
designed to help the immune system fight tumor cells.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
September 30, 2019 11:05 ET (15:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024